BioSpace News Archive

American Society of Nephrology (ASN) Kidney Week 2019 Annual Meeting, taking place November 5-10, 2019, in Washington, D.C.

Spain’s leading pharmaceutical company drives seamless customer engagement across multiple stakeholders using face-to-face, email, and web

Two late-stage microbiome clinical study readouts in ulcerative colitis and C. difficile infection anticipated in 2020

Ocular Therapeutix™, Inc. announced that it has granted non-statutory stock options to purchase up to an aggregate of 54,000 shares of common stock of Ocular Therapeutix to an additional nine, newly-hired Key Account Mangers supporting the commercial launch of DEXTENZA®.

Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development of therapeutics for central nervous system disorders, provided a corporate update and announced its financial results for the third quarter ended September 30, 2019.

Dosed First Patient in Phase 3 Study of APL-2 for Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria

Willow is in the process of completing its application to become DTC eligible in the U.S.

Editas Medicine, Inc., a leading genome editing company, announced that it will host a conference call and webcast on Tuesday, November 12, 2019, at 8:00 a.m. ET to discuss a corporate update and results for the third quarter of 2019.

Forty Seven Inc., a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, November 12, 2019 to report its third quarter 2019 financial results and provide a corporate update..

Worldwide Ocaliva net sales of $61.5 million in the third quarter of 2019 representing 32% growth versus the prior year quarter; increasing full year 2019 worldwide Ocaliva net sales guidance range to between $245 million and $250 million